Answers are grounded in this paper and cite their sources.
Clear cell renal cell carcinoma (ccRCC) is characterized by the dysregulation of cellular oxygen sensing resulting from inactivation of the von Hippel-Lindau (VHL) tumor-suppressor gene. Loss of VHL function leads to constitutive activation of hypoxia-inducible factor (HIF) signaling, with HIF-2α emerging as the dominant oncogenic driver of angiogenesis, metabolic reprogramming, tumor growth, and metastasis. The discovery of a druggable cavity within the HIF-2α PAS-B domain transformed a previously undruggable transcription factor into a therapeutic target and enabled the development of selective HIF-2α inhibitors. Belzutifan, the first approved HIF-2α inhibitor, has demonstrated meaningful clinical activity in VHL disease-associated neoplasms and advanced ccRCC, validating direct inhibition of the VHL-HIF pathway as a therapeutic strategy. More recently, belzutifan in combination with pembrolizumab was approved as adjuvant therapy for patients with resected ccRCC. Separately, the development of next-generation HIF-2α inhibitors, HIF-1β (also known as aryl hydrocarbon receptor nuclear translocator)-targeted degraders, and novel combination strategies, including those incorporating vascular endothelial growth factor-targeted therapies, continues to broaden the therapeutic potential of HIF-directed treatment. In this review, the authors summarize the biologic basis of the VHL-HIF axis, the development of HIF-targeted therapies, key clinical data supporting their use in renal cell carcinoma, and future directions for this rapidly evolving therapeutic class.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: